This review summarizes recent advances in the molecular biology and immunometabolic roles of S100A12 in SA-AKI, emphasizes its systemic versus kidney-specific effects, and discusses its translational potential as a biomarker and therapeutic target, highlighting opportunities and challenges for precision diagnostics and targeted therapies in sepsis-related organ injury. Here, S100A12 is linked to Sepsis.